Create a narrative

Elutia Community

NasdaqCM:ELUT Community

1 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity

Key Takeaways EluPro's FDA clearance and market entry against Medtronic's TYRX could drive significant revenue growth in the antibiotic-eluting envelope space. Strategic partnerships, expanded capacity, and production efficiencies are expected to enhance market penetration, lower costs, and boost margins.

US$7.50

FV

72.8% undervalued

48.32%

Revenue growth p.a.

0

0

0

10 days ago